NCT01609556: First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
- State
- Completed
- Phase
- Phase 1
- People
- 206 taking part
- Started
- 28 Jun 2012
- Primary completion
- 19 Mar 2018
- Arms
- Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W), Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly), Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W), Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)
- Results
- Posted on the registry
- 1 Jun 2012: Trial registered
- 28 Jun 2012: Trial started
- 19 Mar 2018: Trial completed
- 17 Feb 2021: Trial results posted